
Last updated: 2026-09-07 01:22:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vaxcyte, Inc. (PCVX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $61.15, with a market capitalization of $9.10B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $30.81 to $65.00. This page covers its latest market performance, valuation, price trends and company information.
$9.10B | |
$59.73 | |
$121.06 | |
$15.51 | |
$61.17 | |
597.54K | |
1.30M | |
-- | |
$65.00 | |
$30.81 | |
-- | |
-- |
Vaxcyte, Inc. (PCVX) last closed at $61.17 as of 2026-09-04 23:31:00, unchanged from the previous close of $61.17.
During the latest regular trading session, PCVX traded between $15.51 and $121.06, with a volume of 597.54K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Vaxcyte, Inc. (PCVX) moved from $61.16 to $61.15, representing a decline of 0.01% ($0.01).
The stock traded between $58.51 and $62.90 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.04 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 88.7%
PCVX is currently trading at $61.15, placing it 88.7% of the way from its 52-week low of $30.81 to its 52-week high of $65.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 507 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vaxcyte, Inc. (PCVX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.